NovaGo Therapeutics closes $30M Series B led by Neurimmune and Pureos to advance spinal cord injury treatment.
Amount Raised
$30 Million
Round Type
Series B
ZurichBiotechnologyHealth CareTherapeuticsInvestors
Description
NovaGo Therapeutics AG, a clinical-stage biotechnology company, successfully closed a CHF 24 million (USD 30 million) Series B financing round led by Neurimmune and Pureos, with participation from existing and new investors. The round is complemented by non-dilutive funding from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation. Proceeds will be used to advance NovaGo's lead anti-Nogo-A biologic program into a proof-of-concept study in patients with acute spinal cord injury, a fully randomized, double-blind trial enrolling 120 patients across Germany, Spain, and Switzerland. The company is developing treatments targeting Nogo-A, a protein that inhibits nerve fiber regeneration, with the goal of enabling functional recovery in spinal cord injury patients.
Quick answer
NovaGo Therapeutics AG raised $30 Million in a Series B round, dated September 2, 2026. Investors: Neurimmune and Pureos. NovaGo Therapeutics AG is based in Zurich, Switzerland.
- How much did NovaGo Therapeutics AG raise?
- NovaGo Therapeutics AG raised $30 Million in a Series B round on September 2, 2026.
- Who invested in NovaGo Therapeutics AG?
- Neurimmune and Pureos are named as investors in this round.
- What does NovaGo Therapeutics AG do?
- NovaGo Therapeutics AG is a clinical-stage biotechnology company developing anti-Nogo-A biologics for diseases of the central nervous system.
- Where is NovaGo Therapeutics AG based and how big is it?
- NovaGo Therapeutics AG is based in Zurich, Switzerland.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as NovaGo Therapeutics AG that raised within 45 days of this round, from Fundz verified event records.
- GenSight Biologics raised $1.1M (Post-IPO Equity) on October 16, 2026.
- Estuary Biotherapeutics raised $93M (Series A) on October 16, 2026.
- Acta Pharmaceuticals raised $24M (Seed) on October 15, 2026.
- Float Bio raised $140K (Pre-Seed) on October 15, 2026.
- Recursion Pharmaceuticals raised $200M (Post-IPO Equity) on October 15, 2026.
- Os Therapies raised $7.2M on October 15, 2026.
Who to call at NovaGo Therapeutics AG, and when
A new round usually means NovaGo Therapeutics AG is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day NovaGo Therapeutics AG raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at NovaGo Therapeutics AG, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at NovaGo Therapeutics AG. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment NovaGo Therapeutics AG raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Funding Insights
What this usually meansNovaGo Therapeutics AG raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.